{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=48", "query": { "intervention": "Placebo Intravenous", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 2347, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:04:08.477Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00493311", "title": "Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fever" ], "interventions": [ { "name": "IV Placebo", "type": "DRUG" }, { "name": "IV Acetaminophen", "type": "DRUG" }, { "name": "Reference Standard Endotoxin (RSE)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 60, "start_date": "2007-06", "completion_date": "2007-10", "has_results": true, "last_update_posted_date": "2016-10-19", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493311" }, { "nct_id": "NCT03283371", "title": "Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy, Focal Seizures, Partial Seizures" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 67, "start_date": "2018-03-20", "completion_date": "2020-11-18", "has_results": true, "last_update_posted_date": "2021-12-14", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03283371" }, { "nct_id": "NCT01261403", "title": "Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "PDA001", "type": "BIOLOGICAL" }, { "name": "Vehicle Controlled Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2010-12", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 16, "location_summary": "Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01261403" }, { "nct_id": "NCT01951729", "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pre-diabetes" ], "interventions": [ { "name": "Control", "type": "DRUG" }, { "name": "Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP without atropine", "type": "DRUG" }, { "name": "Placebo with atropine", "type": "DRUG" }, { "name": "Xenin-25 with atropine", "type": "DRUG" }, { "name": "GIP with atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 with atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2013-03-13", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951729" }, { "nct_id": "NCT07409272", "title": "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Setidegrasib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "liposomal irinotecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 614, "start_date": "2026-02-17", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 49, "location_summary": "Tucson, Arizona • Fort Smith, Arkansas • Fullerton, California + 43 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07409272" }, { "nct_id": "NCT00265265", "title": "Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cocaine-Related Disorders" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 16, "start_date": "2005-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265265" }, { "nct_id": "NCT06947928", "title": "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Or Metastatic Merkel Cell Carcinoma" ], "interventions": [ { "name": "IFx-Hu2.0", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TuHURA Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2025-12-11", "completion_date": "2032-12-30", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 18, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06947928" }, { "nct_id": "NCT02966028", "title": "Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cardiovascular Diseases", "Cardiovascular Abnormalities", "Calcifications, Vascular", "Endstage Renal Disease", "ESRD", "Coronary Artery Calcification" ], "interventions": [ { "name": "SNF472", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanifit Therapeutics S. A.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 274, "start_date": "2016-11", "completion_date": "2019-09", "has_results": true, "last_update_posted_date": "2021-04-15", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 46, "location_summary": "Bakersfield, California • Chula Vista, California • Escondido, California + 42 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02966028" }, { "nct_id": "NCT06989567", "title": "A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "L-citrulline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Asklepion Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 120, "start_date": "2025-07-25", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06989567" }, { "nct_id": "NCT00558311", "title": "Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aneurysmal Subarachnoid Hemorrhage" ], "interventions": [ { "name": "Clazosentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1157, "start_date": "2007-12-14", "completion_date": "2010-07-13", "has_results": false, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-16T10:04:08.477Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00558311" } ] }